# Scipher Medicine Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/scipher-medicine

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.sciphermedicine.com
- Total disclosed funding: $222M
- Latest round: Series D (Jan 30, 2022)
- Investors on record: 13

## About

Based in Massachusetts, US, Scipher Medicine Corporation (Scipher Medicine) was founded in 2014 by co-founders Dr. Joe Loscalzo and Dr. Albert-Laszlo Barabasi. In 2003, the founders started building the map of human disease biology that explains how proteins expressed from the human genome interact to cause specific diseases. In 2016, researchers of the company began to develop predictive drug response tests. After studying and surveying the healthcare community to identify major therapeutic and financial pressure points, in 2017 Scipher applied its analysis to create a blood test for predicting medication response to anti-TNF therapies. In March 2021, Scipher Medicine Corporation raised USD 82 million in series C funding co-led by new investor aMoon and returning investor Northpond Ventures.

Scipher Medicine Corporation develops a suite of drug development platforms that analyze genetic information to determine suitable therapeutics using machine learning and artificial intelligence. The firm's offerings include ScipherIx, a protein-mapping platform for identifying patient population subgroups; ScipherDx, a drug response prediction platform; and ScipherRx, a drug development platform utilizing gene expression data and applying them to ScipherIx.

The company plans to extend commercial efforts for its patient molecular signature test, PrismRA®, to ensure that rheumatoid arthritis patients are administered effective personalized therapy from the onset, as well as data partnerships to explore novel treatment targets based on its broad and growing patient clinical-genomic database created from studied patients.

## Funding rounds

- Series D, Jan 30, 2022, $110M — Neuberger Berman - Fund of Funds and Secondary, Khosla Ventures, Laurion Capital Management, Monashee Investment Management, Alumni Ventures Group, Cowen Investment Management, Echo Health Ventures, aMoon, Optum Ventures, Northpond Ventures, Hitachi Ventures
- Series C, Mar 24, 2021, $82M — Khosla Ventures, Alumni Ventures Group, Echo Health Ventures, aMoon, Northpond Ventures
- Series B, Feb 19, 2020 — Optum Ventures
- Series B, May 8, 2019, $20M — Khosla Ventures, Alumni Ventures Group, Granpool, Tachyons Ventures, Northpond Ventures
- Series A, Sep 6, 2018, $10M — Khosla Ventures

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series B, Series C, Series D
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B, Series C, Series D
- Granpool (https://capitalatlas.ai/funds/granpool) — Series B
- Tachyons Ventures — Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B, Series C, Series D
- Optum Ventures (https://capitalatlas.ai/funds/optum-ventures) — Series B, Series D
- Echo Health Ventures (https://capitalatlas.ai/funds/echo-health-ventures) — Series C, Series D
- aMoon (https://capitalatlas.ai/funds/amoon) — Series C, Series D
- Neuberger Berman - Fund of Funds and Secondary (https://capitalatlas.ai/funds/neuberger-berman-fund-of-funds-and-secondary) — Series D
- Laurion Capital Management — Series D
- Monashee Investment Management — Series D
- Cowen Investment Management — Series D
- Hitachi Ventures (https://capitalatlas.ai/funds/hitachi-ventures) — Series D